Concord Biotech Q1 Results: Earnings Call Scheduled for Aug 3 to Discuss Q1FY27 Performance
Concord Biotech Limited announces its Q1FY27 earnings call for August 3, 2026. Key executives including Sudhir Vaid and Raviraj Karia will discuss standalone and consolidated financial results. The call complies with SEBI Regulation 30 disclosures.

*this image is generated using AI for illustrative purposes only.
Concord Biotech Limited will host an earnings conference call on Monday, August 03, 2026, at 3:30 PM IST to discuss its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The event provides investors with direct access to management for insights into the company's operational performance and strategic outlook following the declaration of its Q1FY27 results.
The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of Schedule III. Paritosh Trivedi, Company Secretary and Compliance Officer, signed the submission to the National Stock Exchange of India Limited and BSE Limited on July 28, 2026. The filing confirms that the earnings call invite has been enclosed with the exchange submissions for record-keeping purposes.
Management Participants
Senior leadership from Concord Biotech will participate in the discussion to address investor queries regarding the quarterly performance. The confirmed participants include:
| Executive | Designation |
|---|---|
| Sudhir Vaid | Chairman & Managing Director |
| Ankur Vaid | Joint Managing Director and CEO |
| Raviraj Karia | Chief Financial Officer |
| Prakash Sajnani | AVP, Accounts & Finance |
Conference Call Details
The conference call is organized in association with IIFL. Participants can join via pre-registration through the provided Diamond Pass link or by dialing the designated numbers. The schedule accommodates global investors with simultaneous time zone conversions listed for Hong Kong, Singapore, the UK, and the USA.
| Region | Dial-in Number |
|---|---|
| India (Primary) | +91 22 6280 1259 / +91 22 7115 8160 |
| USA | 1-866 746 2133 |
| UK | 0-808 101 1573 |
| Singapore | 800-101 2045 |
| Hong Kong | 800-964 448 |
For further information or registration assistance, investors may contact Naman Bagrecha, Rahul Jeewani, Aman Goyal, or Vighnesh Indure at IIFL Capital Markets using the provided contact details.
Historical Stock Returns for Concord Biotech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.02% | -5.91% | -0.46% | +2.79% | -32.67% | +33.23% |
How might Concord Biotech's Q1FY27 revenue and margin performance influence its valuation relative to generic pharmaceutical peers in the current market cycle?
What specific strategic initiatives or pipeline developments is management likely to highlight to justify future growth projections during the conference call?
Will the company address any potential regulatory headwinds or supply chain disruptions that could impact its operational outlook for the remainder of FY27?


































